Kodiak Sciences’ tarcocimab tedromer—branded Zenkuda—posted positive Phase 3 results in diabetic retinopathy across the Glow2 program, beating a sham procedure and setting up an accelerated, multi-indication biologics license application (BLA) strategy. The update also supported renewed investor confidence after prior setbacks tied to ocular efficacy expectations. According to the report, 62.5% of treated patients achieved at least a two-step improvement in diabetic retinopathy severity score versus 3.3% in the sham group. The company’s next planned catalysts include additional Phase 3 readouts during the year, alongside label expansion ambitions. For biotech investors and partners, the win places Kodiak back on track for a faster path to U.S. registration, with platform implications for related antibody-bio-polymer conjugate (ABC) assets and inflammation-linked retinal programs.